Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

About Human Respiratory Syncytial Virus Drugs

Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system.

Technavio’s analysts forecast the global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global human respiratory syncytial virus drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent respiratory syncytial virus infections.

The market is divided into the following segments based on geography:

• Europe
• ROW
• US

Technavio's report, Global Human Respiratory Syncytial Virus Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• AstraZeneca
• AbbVie
• GSK
• Teva Pharmaceutical

Other prominent vendors

• Ablynx
• ADMA Biologics
• Alnylam Pharmaceuticals
• Ark Biosciences
• Aviragen Therapeutics
• Bavarian Nordic
• Boehringer Ingelheim
• Gilead Sciences
• ImmunoVaccine Technologies
• Johnson & Johnson
• Kyowa Hakko Kirin
• Medivir
• Mucosis
• Mymetics Corporation
• Novavax
• Regeneron Pharmaceuticals
• ReViral
• Vaxart

Market driver

• Novel diagnostic tools increase patient population.
• For a full, detailed list, view our report

Market challenge

• Continuous change in guidelines from healthcare organizations impacts market growth.
• For a full, detailed list, view our report

Market trend

• Emergence of new entrants likely to change market dynamics.
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Press Release

Technavio Announces the Publication of its Research Report – Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global human respiratory syncytial virus drugs market: AstraZeneca, AbbVie, GSK, and Teva Pharmaceutical.

Other Prominent Vendors in the market are: Ablynx, ADMA Biologics, Alnylam Pharmaceuticals, Ark Biosciences, Aviragen Therapeutics, Bavarian Nordic, Boehringer Ingelheim, Gilead Sciences, ImmunoVaccine Technologies, Johnson & Johnson, Kyowa Hakko Kirin, Medivir, Mucosis, Mymetics, Novavax, Regeneron Pharmaceuticals, ReViral, and Vaxart.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period. For instance, in January 2016, Mucosis received $4.1 million funding from the Wellcome Trust, a global charitable foundation focusing on improving health, to advance SynGEM, its proprietary intranasal RSV vaccine, into phase I and IIa human clinical trials. In September 2015, OrbiMed and Edmond de Rothschild Investment Partners co-led a $21 million series A round in ReViral, a London-based company that is developing RV521, a drug for the treatment of RSV. In June 2015, Immunovaccine commenced phase I clinical study of its DPX-RSV vaccine. The vaccine candidate contains a specific target and a viral protein that is active on the surface of infected cells. It is believed that an immune response to the specific target will limit the severity of RSV infection. The entry of new companies will certainly pave the way for the development of novel products for the treatment of RSV.”

According to the report, one driver in the market is presence of large patient pool fuels market growth. RSV is the leading cause of lower respiratory tract infections in infants and young children. Each year, 4-5 million children younger than four years of age acquire an RSV infection, and more than 0.12 million are hospitalized annually in the US because of this infection. For example, approximately 25 to 40 out of 100 individuals with RSV have signs or symptoms of pneumonia or bronchiolitis. Five to 20 out of 1,000 require hospitalization. Also, adults with compromised immune systems and of ages 65 and older are also at a higher risk of severe disease. In the US, on average, RSV leads to 57,257 hospitalizations among children of ages below 5 years; 2.1 million outpatient visits among children less than 5 years; and 0.17 million hospitalizations and 14,000 death cases among adults of ages more than 65 years. The presence of this large RSV patient pool with highly unmet medical needs with single approved therapy is expected to drive the market growth during the forecast period.

Further, the report states that one challenge in the market is continuous change in guidelines from healthcare organizations impacts market growth. The dynamic nature of guidelines from the American Academy of Pediatrics Committee on Infectious Disease (AAPCID) restricted the patients eligible for preventive treatment with Synagis, the leading drug in the market. Synagis received US FDA approval in June 1998 for the treatment of lower respiratory infection caused by RSV. Since then, the AAPCID updated its guidance related to Synagis four times. The recent update (2014) states that the use of Synagis prophylaxis in infants and children should be restricted to those that are at increased risk of RSV infection. Earlier, the definition of high-risk children on the Synagis package was not included. Most payers in the US have implemented these guidelines in 2014.



Companies Mentioned

Other Prominent Vendors in the market are: Askon Engineers, Bio JetDrier, HOKWANG INDUSTRIES, Taishan Jieda Electrical Industrial, Panasonic, and Palmer Fixture.